Transformation of HIV from pandemic to low-endemic levels: A public health approach to combination prevention

The Lancet

Volumn 384, Issue 9939, 2014, Pages 272-279

  Jones, Alexandra ^a   Cremin, Ide ^b   Abdullah, Fareed ^c   Idoko, John ^a,d   Cherutich, Peter ^e   Kilonzo, Nduku ^f   Rees, Helen ^g   Hallett, Timothy ^b   O'Reilly, Kevin ^h   Koechlin, Florence ^h   Schwartlander, Bernhard ⁱ   De Zalduondo, Barbara ^j   Kim, Susan ^a   Jay, Jonathan ^a   Huh, Jacqueline ^a   Piot, Peter ^k   Dybul, Mark ^a,l  

^a GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c South Africa National AIDS Council (SANAC)   (South Africa)

^d NATIONAL AGENCY FOR THE CONTROL OF AIDS   (Nigeria)

^e National AIDS/STD Control Programme   (Kenya)

^f Liverpool Voluntary Counseling and Testing and Care   (Kenya)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ Department of Evidence Strategy and Results ^*  (Switzerland)

^j UNAIDS   (Switzerland)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^l TUBERCULOSIS AND MALARIA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BEHAVIOR CHANGE; CIRCUMCISION; CONDOM USE; DISEASE TRANSMISSION; ENDEMIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PANDEMIC; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PUBLIC HEALTH SERVICE; RISK ASSESSMENT;

ANTI-HIV AGENTS; ENDEMIC DISEASES; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PANDEMICS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PUBLIC HEALTH; RISK FACTORS;

EID: 84904514440     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62230-8     Document Type: Article

References (109)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. November, 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/ gr2013/UNAIDS- Global-Report-2013-en.pdf (accessed Oct 8, 2013).
2. WHO. Global update on HIV treatment 2013: results, impact and opportunities. June, 2013. http://apps.who.int/iris/bitstream/10665/85326/1/ 9789241505734-eng.pdf (accessed Aug 3, 2013).
3. Stover J, Hallett T, Wu Z, et al. How can we get to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV and AIDS. 17th International Conference on AIDS and STIs in Africa; Cape Town, South Africa; Dec 7-11, 2013. Oral abstract. http://www.icasa2013southafrica.org/images/stories/ICASA-presentations/Sunday/ Auditorium%20 1/12h45/Impact%20of %20Combined%20Prevention.pdf (accessed Feb 4, 2014).
4. Gregson S, Garnett GP, Nyamukapa CA, et al. HIV decline associated with behavior change in eastern Zimbabwe. Science 2006; 311: 664-66.
5. Gregson S, Gonese E, Hallett TB, et al. HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. Int J Epidemiol 2010; 39: 1311-23.
6. Green EC, Halperin DT, Nantulya V, Hogle JA. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav 2006; 10: 335-46.
7. International Group on Analysis of Trends in HIV Prevalence and Behaviours in Young People in Countries most Affected by HIV. Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV. Sex Transm Infect 2010; 86 (suppl 2): ii72-83.
8. Shisana O, Rehle T, Simbayi LC, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: a turning tide among teenagers? Cape Town: HSRC Press, 2009.
9. Central Statistics Office. 2008 Botswana AIDS Impact Survey III. November, 2009. http://www.hiv.gov.bw/sites/default/files/documents/baisiii- report%5B1%5D.pdf (accessed April 29, 2013).
10. Zenilman JM, Weisman CS, Rompalo AM, et al. Condom use to prevent incident STDs: the validity of self-reported condom use. Sex Transm Dis 1995; 22: 15-21.
11. Sigall H, Aronson E, Van Hoose T. The cooperative subject: myth or reality? J Exp Soc Psychol 1970; 6: 1-10.
12. Weir SS, Roddy RE, Zekeng L, Ryan KA. Association between condom use and HIV infection: a randomised study of self reported condom use measures. J Epidemiol Community Health 1999; 53: 417-22.
13. Allen S, Meinzen-Derr J, Kautzman M, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 2003; 17: 733-40.
14. Zaba B, Todd J, Biraro S, et al. Diverse age patterns of HIV incidence rates in Africa. XVIIth International AIDS Conference. Mexico; August, 2008. Oral abstract TUAC0201. http://www.iasociety.org/Abstracts/A200720876.aspx (accessed April 29, 2013).
15. UNAIDS. Condoms and HIV prevention: position statement by UNAIDS, UNFPA and WHO. March 19, 2009. http://www.unaids. org/en/resources/presscentre/ featurestories/2009/march/20090319 preventionposition/(accessed April 29, 2013).
16. Carey RF, Lytle CD, Cyr WH. Implications of laboratory tests of condom integrity. Sex Transm Dis 1999; 26: 216-20.
17. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; 1: CD00325.
18. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44: 1303-12.
19. Ng M, Gakidou E, Levin-Rector A, Khera A, Murray CJ, Dandona L. Assessment of population-level effect of Avahan, an HIV-prevention initiative in India. Lancet 2011; 378: 1643-52.
20. Ngugi EN, Plummer FA, Simonsen JN, et al. Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet 1988; 2: 887-90.
21. Rojanapithayakorn W. The 100% condom use programme in Asia. Reprod Health Matters 2006; 14: 41-52.
22. UNAIDS. Global report: report on the global AIDS epidemic 2010. http://www.unaids.org/globalreport/global-report.htm (accessed April 29, 2013).
23. Foss AM, Watts CH, Vickerman P, Heise L. Condoms and prevention of HIV. BMJ 2004; 329: 185-86.
24. Kenya National Bureau of Statistics. Kenya Demographic and Health Survey, 2008-2009. June, 2010. http://www.measuredhs. com/pubs/pdf/FR229/FR229.pdf (accessed April 29, 2013).
25. Global Industry Analysts. Condoms: a global strategic business report. October, 2012. http://www.researchandmarkets.com/reports/338816/condoms-global- strategic-business-report (accessed April 29, 2013).
26. Beksinska M, Smit J, Joanis C, Usher-Patel M, Potter W. Female condom technology: new products and regulatory issues. Contraception 2011; 83: 316-21.
27. Coffey PS, Kilbourne-Brook M, Austin G, Seamans Y, Cohen J. Short-term acceptability of the PATH Woman's Condom among couples at three sites. Contraception 2006; 73: 588-93.
28. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2: e298.
29. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-66.
30. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643-56.
31. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012; 26: 609-15.
32. Njeuhmeli E, Forsythe S, Reed J, et al. Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med 2011; 8: e1001132.
33. Hankins C, Forsythe S, Njeuhmeli E. Voluntary medical male circumcision: an introduction to the cost, impact, and challenges of accelerated scaling up. PLoS Med 2011; 8: e1001127.
34. Westercamp N, Bailey RC. Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review. AIDS Behav 2007; 11: 341-55.
35. WHO. Country experiences in the scale-up of male circumcision in the Eastern and Southern Africa Region: two years and counting. July 2009. http://www.who.int/hiv/pub/malecircumcision/meetingreport-june09/en/index.html (accessed Feb 4, 2014).
36. Dickson KE, Tran NT, Samuelson JL, et al. Voluntary medical male circumcision: a framework analysis of policy and program implementation in eastern and southern Africa. PLoS Med 2011; 8: e1001133.
37. McIntyre JA. Can devices for adult male circumcision help bridge the implementation gap for HIV prevention services? J Acquir Immune Defic Syndr 2011; 58: 506-08.
38. Zimbabwean MPs to be circumcised as part of HIV/Aids campaign. The Telegraph (London); May 20, 2012. http://www.telegraph.co.uk/news/worldnews/ africaandindianocean/zimbabwe/9278524/Zimbabwean-MPs-to-be-circumcised-as-part- of-HIVAids-campaign.html (accessed April 29, 2013).
39. Mattson CL, Campbell RT, Bailey RC, Agot K, Ndinya-Achola JO, Moses S. Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS One 2008; 3: e2443.
40. Agot KE, Kiarie JN, Nguyen HQ, Odhiambo JO, Onyango TM, Weiss NS. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 44: 66-70.
41. Kong X, Kigozi G, Nalugoda F, et al. Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am J Epidemiol 2012; 176: 875-85.
42. Grulich AE, Hendry O, Clark E, Kippax S, Kaldor JM. Circumcision and male-to-male sexual transmission of HIV. AIDS 2001; 15: 1188-89.
43. Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005; 39: 82-89.
44. Cohen MS, Chen YQ, McCauley M, et al, and the HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
45. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339: 966-71.
46. Johnson LF, Hallett TB, Rehle TM, Dorrington RE. The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface 2012; 9: 1544-54.
47. Smith MK, Powers KA, Muessig KE, Miller WC, Cohen MS. HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med 2012; 9: e1001260.
48. Centers for Disease Control and Prevention. CDC fact sheet: new infection in the United States. December, 2012. http://www.cdc. gov/nchhstp/newsroom/ docs/2012/hiv-infections-2007-2010.pdf (accessed April 30, 2013).
49. Bezemer D, de Wolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22: 1071-77.
50. Dybul M, Bolan R, Condoluci D, et al. Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis 2002; 185: 1818-21.
51. Keiser O, Anastos K, Schechter M, et al, and the ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA). Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13: 870-79.
52. Mugglin C, Althoff K, Wools-Kaloustian K, et al. Immunodeficiency at the start of ART: global view. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA; March 5-8, 2012. Abstract.
53. Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr 2012; 61: 116-19.
54. Grant RM, Lama JR, Anderson PL, et al, and the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-99.
55. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al, and the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
56. Baeten JM, Donnell D, Ndase P, et al, and the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
57. Haberer JE, Baeten JM, Campbell J, et al. Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Med 2013; 10: e1001511.
58. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA; March 3-6, 2013. Abstract 26LB.
59. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011; 53: 1265-70.
60. Parikh UM, Mellors JW HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. Clin Infect Dis 2012; 55: 303-04.
61. van de Vijver DA, Nichols BE, Abbas UL, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS 2013; 27: 2943-51.
62. Pretorius C, Stover J, Bollinger L, Bacaër N, Williams B. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5: e13646.
63. The Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011 11: 171-80.
64. WHO. UNODC, UNAIDS. Technical guide for countries to set targets for universal access to HIV prevention, treatment-2012 revision. Geneva: WHO, 2012.
65. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376: 268-84.
66. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet 2008; 372: 764-75.
67. Baird SJ, Garfein RS, McIntosh CT, Özler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 2012; 379: 1320-29.
68. Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis 2013; 13: 65-76.
69. PEPFAR. PEPFAR blueprint: creating an AIDS free generation. November, 2012. http://www.pepfar.gov/documents/organization/201386.pdf (accessed Feb 4, 2014).
70. NACC and NASCOP. Kenya AIDS Epidemic update 2011. Nairobi: NACC and NASCOP, 2012. http://www.unaids.org/en/dataanalysis/knowyourresponse/ countryprogressreports/2012count ries/ce-KE-Narrative-Report.pdf (accessed April 29, 2013).
71. Bärnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell ML. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS 2008; 22: 139-44.
72. Tanser F, Bärnighausen T, Newell ML. Identification of localized clusters of high HIV incidence in a widely disseminated rural South African epidemic: a case for targeted intervention strategies. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011.
73. Cohen J. HIV prevention. Halting HIV/AIDS epidemics. Science 2011; 334: 1338-40.
74. Kenya National AIDS Control Council. Analysis of HIV prevention response and modes of HIV transmission. Nairobi: National AIDS Control Council, 2009. http://www.nacc.or.ke/images/stories/Documents/KenyaMOT22March09Final.pdf (accessed April 29, 2013).
75. Bertozzi SM, Laga M, Bautista-Arredondo S, Coutinho A. Making HIV prevention programmes work. Lancet 2008; 372: 831-44.
76. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008; 372: 845-59.
77. Cuadros DF, Awad SF, Abu-Raddad LJ. Mapping HIV clustering: a strategy for identifying populations at high risk of HIV infection in sub-Saharan Africa. Int J Health Geogr 2013; 12: 28.
78. Buse K, Dickinson C, Sidibé M. HIV: know your epidemic, act on its politics. J R Soc Med 2008; 101: 572-73.
79. The People Living with HIV Stigma Index. London: International Planned Parenthood Federation, 2012. http://www.stigmaindex.org/(accessed June 26, 2012).
80. Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 2009; 374: 416-22.
81. Schwartländer B, Stover J, Hallett T, et al, and the Investment Framework Study Group. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377: 2031-41.
82. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet 2011; 378: 515-25.
83. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9: e1001245.
84. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 2013; 27: 447-58.
85. Bärnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention Proc Natl Acad Sci USA 2012; 109: 21271-76.
86. Shelton JD. A tale of two-component generalised HIV epidemics. Lancet 2010; 375: 964-66.
87. Bellan SE, Fiorella KJ, Melesse DY, Getz WM, Williams BG, Dushoff J. Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. Lancet 2013; 381: 1561-69.
88. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8: e1001123.
89. Hallett TB, Gregson S, Lewis JJC, Lopman BA, Garnett GP. Behaviour change in generalised HIV epidemics: impact of reducing cross-generational sex and delaying age at sexual debut. Sex Transm Infect 2007; 83 (suppl 1): i50-54.
90. Sullivan PS, Carballo-Diéguez A, Coates T, et al. Successes and challenges of HIV prevention in men who have sex with men. Lancet 2012; 380: 388-99.
91. Gomez GB, Bórquez A, Caceres CF, et al. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med 2012; 9: e1001323.
92. Woosley RL, Cossman J. Drug development and the FDA's Critical Path Initiative. Clin Pharmacol Ther 2007; 81: 129-33.
93. WHO, UNAIDS. Operational guidance for scaling up male circumcision services for HIV prevention. Geneva: World Health Organization, 2008. http://whqlibdoc.who.int/publications/2008/9789241597463-eng.pdf (accessed April 29, 2013).
94. Foege WH. House on fire: the fight to eradicate smallpox. Berkeley: University of California Press, 2011.
95. Jegede AS. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med 2007; 4: e73.
96. Wheelock A, Eisingerich AB, Gomez GB, et al. Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open 2012; 2: e001234.
97. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One 2012; 7: e28238.
98. Nel AM, Mitchnick LB, Risha P, Muungo LT, Norick PM. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt) 2011; 20: 1207-14.
99. International Partnership for Microbicides. The Ring Study. Silver Springs: International Partnership for Microbicides. http://www.ipmglobal.org/ the-ring-study (accessed April 29, 2013).
100. UNAIDS. Together we will end AIDS. Geneva: World Health Organization, 2012.
101. Measure DHS, International ICF. DHS overview. Calverton: Measure DHS, ICF International. http://www.measuredhs.com/What-We-Do/Survey-Types/DHS.cfm (accessed April 29, 2013).
102. Incidence Assay Critical Path Working Group. More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med 2011; 8: e1001045.
103. UNAIDS. Combination HIV prevention: tailoring and coordinating biomedical, behavioural and structural strategies to reduce new HIV infections. Geneva: Joint United Nations Programme on HIV/AIDS, 2010. http://www.unaids.org/ en/media/unaids/contentassets/documents/unaidspublication/2011/ 20111110-JC2007-Combination-Prevention-paper-en.pdf (accessed April 29, 2013).
104. Ghys PD, Kufa E, George MV. Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics. Sex Transm Infect 2006; 82 (suppl 1): i52-56.
105. Zaba B, Boerma T, White R. Monitoring the AIDS epidemic using HIV prevalence data among young women attending antenatal clinics: prospects and problems. AIDS 2000; 14: 1633-45.
106. Padian NS, McCoy SI, Manian S, Wilson D, Schwartländer B, Bertozzi SM. Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr 2011; 58: e23-28.
107. Padian NS, Holmes CB, McCoy SI, Lyerla R, Bouey PD, Goosby EP. Implementation science for the US President's Emergency Plan for AIDS Relief (PEPFAR). J Acquir Immune Defic Syndr 2011; 56: 199-203.
108. Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr 2010; 55 (suppl 1): S27-31.
109. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011; 8: 62-72.